Diabetic Foot Skin Infection Treatment Guidelines

Infection Severity Classification and Treatment

For a diabetic patient with a skin infection on the foot, classify the infection severity first, then treat mild infections with oral clindamycin or amoxicillin-clavulanate for 1-2 weeks, moderate infections with levofloxacin or ciprofloxacin plus clindamycin for 2-3 weeks, and severe infections with IV vancomycin plus piperacillin-tazobactam for 2-4 weeks 1, 2
The American College of Physicians recommends classifying infection severity based on clinical presentation, with mild infection involving only skin and subcutaneous tissue, moderate infection involving deeper tissues or more extensive cellulitis, and severe infection involving systemic toxicity or metabolic instability 2

For mild infections, first-line choice is amoxicillin-clavulanate 875 mg PO twice daily, with alternative options including clindamycin 300-450 mg PO three times daily, dicloxacillin 500 mg PO four times daily, and cephalexin 500 mg PO four times daily 1, 2, 3
For moderate infections, first-line choice is levofloxacin 750 mg PO/IV daily plus clindamycin 300-450 mg PO/IV three times daily, with alternative options including piperacillin-tazobactam 3.375 g IV every 6 hours, ampicillin-sulbactam 3 g IV every 6 hours, ertapenem 1 g IV once daily, and moxifloxacin 400 mg PO/IV once daily 1, 2, 3
For severe infections, first-line choice is vancomycin 15-20 mg/kg IV every 8-12 hours plus piperacillin-tazobactam 4.5 g IV every 6 hours, with alternative broad-spectrum agents to combine with vancomycin including ceftazidime 2 g IV every 8 hours, cefepime 2 g IV every 8-12 hours, imipenem-cilastatin 500 mg IV every 6 hours, and aztreonam 2 g IV every 8 hours 1, 2

Empirically cover MRSA if local MRSA rates exceed 50% for mild infections or 30% for moderate infections, prior inappropriate antibiotic use, recent hospitalization, chronic wounds or osteomyelitis present, or male gender 1, 2
MRSA-active agents include vancomycin 15-20 mg/kg IV every 8-12 hours, linezolid 600 mg PO/IV twice daily, and daptomycin 4-6 mg/kg IV once daily 1, 2
Cover Pseudomonas only if previously isolated from the affected site within recent weeks, macerated wounds with frequent water exposure, moderate or severe infection in patients residing in Asia or North Africa, with Pseudomonas-active agents including piperacillin-tazobactam, ciprofloxacin, ceftazidime, and cefepime 1, 2, 3

Evaluate clinical response daily for inpatients and every 2-5 days for outpatients, with primary indicators of improvement including resolution of local inflammation, resolution of systemic symptoms, and decreased purulent drainage 1, 2
Once culture results return, narrow antibiotics to target identified pathogens, focusing on virulent species like S. aureus and group A/B streptococci, and consider adjusting therapy if no improvement after 4 weeks of appropriate therapy 1, 2, 3

The Infectious Diseases Society of America (IDSA) recommends classifying infection severity to determine the dual antibiotic regimen, with vancomycin and piperacillin-tazobactam for severe infections, or levofloxacin and clindamycin for moderate infections 4

For severe polymicrobial infections, the IDSA guideline recommends vancomycin 15-20 mg/kg IV every 8-12 hours PLUS piperacillin-tazobactam 4.5 g IV every 6 hours for 2-4 weeks 4
For moderate polymicrobial infections, the IDSA guideline recommends levofloxacin 750 mg PO/IV daily PLUS clindamycin 300-450 mg PO/IV three times daily for 2-3 weeks 4

The IDSA guideline recommends empiric MRSA coverage with vancomycin when local MRSA rates exceed 50% for mild infections or 30% for moderate infections, or when severe infection is present 4
Pseudomonas-active agents, such as piperacillin-tazobactam, ciprofloxacin, ceftazidime, and cefepime, should be considered for patients with recent water exposure, macerated wounds, or residence in warm climates 4

Agents providing anaerobic coverage, such as piperacillin-tazobactam, ampicillin-sulbactam, ertapenem, metronidazole, and clindamycin, should be considered for patients with chronic, previously treated, or severe diabetic infections 4
Treatment duration should be based on clinical response, with mild infections typically requiring 1-2 weeks, moderate infections requiring 2-3 weeks, and severe infections requiring 2-4 weeks 4

Once culture results return, antibiotics should be narrowed to target identified pathogens, focusing on virulent species such as S. aureus and group A/B streptococci 4
Surgical debridement of all necrotic tissue is essential, and additional critical measures include pressure offloading, vascular assessment, and optimization of glycemic control 4